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Abstract
The 2020 COVID-19 pandemic has had a profound impact on the clinical research enterprises
at the 60 Clinical and Translational Science Award (CTSA) Hubs throughout the nation. There
was simultaneously a need to expand research to obtain crucial data about disease prognosis
and therapy and enormous limitations on conducting research as localities and institutions lim-
ited travel and person-to-person contact. These imperatives resulted in major changes in the
way research was conducted, including expediting Institutional Review Board review, shifting
to remote interactions with participants, centralizing decision-making in prioritizing research
protocols, establishing biobanks, adopting novel informatics platforms, and distributing study
drugs in unconventional ways. National CTSA Steering Committee meetings provided an
opportunity to share best practices and develop the idea of capturing the CTSA program expe-
riences in a series of papers. Here we bring together the recommendations from those papers in
a list of specific actions that research sites can take to strengthen operations and prepare for
similar future public health emergencies. Most importantly, creative innovations developed
in response to the COVID-19 pandemic deserve serious consideration for adoption as new stan-
dards, thus converting the painful trauma of the pandemic into “post-traumatic growth” that
makes the clinical research enterprise stronger, more resilient, and more effective.
Introduction
The first four cases of what would later be called severe acute respiratory syndrome-related coro-
navirus 2 (SARS-CoV-2) infection, or COVID-19, were reported in Wuhan, China, on
December 31, 2019 [1,2], although later studies indicate that individuals probably were infected
earlier, perhaps even in November [3–5]. The nucleotide sequence of the virus was made public
by a consortium of Chinese and Australian institutions on January 10, 2020 [6], establishing the
causative agent as a coronavirus with genetic similarities to SARS-CoV and Middle East
Respiratory Syndrome (MERS). Although its mode of transmission was unclear, early anecdotal
reports indicated that single patients could infect large numbers of health care workers, raising
the likelihood that person-to-person spread could occur readily, which was confirmed by
January 21, 2020 [7]. Later, it was appreciated that asymptomatic individuals could spread
the virus to large numbers of contacts outside of the health care setting [8]. The first US case
was reported in a traveler who returned to Washington State fromWuhan on January 15, 2020;
the first European cases of COVID-19 were reported on January 24 in France [9]. The US par-
tially restricted travel to the United States from China on January 30 and declared the disease a
Public Health Emergency on January 31. On the same day federal officials ordered a 14-day
quarantine for a group of 195 citizens repatriated from China, but did not restrict travel from
Europe.
Based on the DNA sequence of the virus a polymeric chain reaction test to detect SARS-CoV-
2 viral DNA was developed by German investigators at Berlin’s Charité Hospital [10] and later
adopted by the WHO, but not by the US CDC or Food and Drug Administration (FDA). The
CDC prepared its own test but encountered substantial delays, thus seriously limiting and delay-
ing testing in the United States [11,12]. For example, the CDC website on March 1 indicated it
could perform only 350 tests per day and that it had material for only 75,000 tests for the entire
country. In contrast, by March 16, the WHO had already distributed 1.5 million tests to 120
countries [13]. Data from Italy, Japan, South Korea, and Iran in early March demonstrated
the enormously rapid spread of the virus, which overwhelmed
medical facilities and taxed health care professionals to their limits.
The WHO declared COVID-19 a pandemic on March 11 and that
was soon followed by outbreaks in New York, New Jersey,
Connecticut, Massachusetts, and other states. For example, on
March 2, the US reported just 16 new cases that day, but by
March 30, it reported 21,469 new cases.
The Clinical and Translational Science Award (CTSA)
Consortium’s Response
The National Institutes of Health (NIH) through its National
Center for Advancing Translational Science (NCATS) supports
approximately 60 academic hubs in its CTSA program. Nearly
all of the CTSA hubs are affiliated with one or more health care
systems across the country and are committed to the goal of
enhancing national capacity, methods, and processes in clinical
and translational research, focusing on the local needs of their
communities. As the COVID-19 pandemic spread, the national
CTSA Steering Committee devoted increasing attention to sharing
best practices among CTSA sites as each hub addressed the chal-
lenges it faced in responding to the local manifestations of the pan-
demic, and as the Steering Committee collectively focused on
advancing discovery and translational science targeting COVID-19
broadly. From those Steering Committee meetings emerged plans to
capture the creative ideas developed by CTSA hubs in a series of
papers focusing on different elements in the clinical research enter-
prise (Fig. 1). The outcome is this special issue of the Journal of
Clinical and Translational Sciences.
Each paper is flexibly organized by the following template:
1. What were the practices before the COVID-19 pandemic?
2. How were practices altered/redefined/modified/streamlined
to address the challenges and exigencies of the COVID-19
pandemic?
3. What were the key lessons learned?
4. Which, if any, extraordinary practices developed as a response
to COVID-19 should now become standard, and which, if any
raised sufficient concerns that they should not be continued or
perhaps even considered in the future in the face of a similar
public health challenge?
5. If a similar public health challenge occurred in the future, what
would be the sequence of actions you recommend to take in
response?
We coupled this initiative with an extensive survey of the CTSA
hubs created by the University of Rochester Center for Leading
Innovation and Collaboration (CLIC) Survey Team by integrating
the questions proposed by the each of the writing groups
(Supplementary Table). A total of 60 hubs responded, providing
robust data about measures that the hubs implemented, along with
an assessment of best practices. The detailed results of the survey
are included in the individual manuscripts. The most dramatic
finding was that 87% of the CTSA hubs indicated that they were
involved in creating institutional COVID-19-related governing
policies, highlighting the importance of CTSAs in shaping the
clinical research enterprise.
This theme issue ofThe Journal of Clinical Translational Science
brings all of these papers together, and this paper provides a sum-
mary of the key recommendations proposed by the authors of each
of the papers. We have focused our recommendations on things to
do now (Table) based on the CTSA experience and best practices
because careful planning now will facilitate and speed implemen-
tation of measures to address a future public health challenge. The
same table should serve as a checklist if we are confronted with
another public health emergency of comparable magnitude. In this
way, we hope to provide a “playbook” as a resource for those called
upon to lead the clinical research enterprise at their institution in
response to new public local, regional, or global health crises.
The topics covered in Table 1 are wide ranging because major
public health emergencies impact virtually every phase of research
operations. The impact of COVID-19 on educational programs has
been particularly profound, requiring an enormous effort to sus-
tain trainees’ productivity. This topic is being addressed in a sep-
arate publication by the CTSA career and workforce development
group [14]. Based on a survey of TL1 trainees and KL2 scholars,
they found that lack of access to research facilities, clinics, team
members, and human subjects, coupled with the need for home-
schooling, were major challenges. Strategies to maintain research
productivity involved trying to focus on writing, time management,
virtual connections with colleagues, and shifting to research activ-
ities not requiring laboratory/clinic settings. They also described
serious concerns by trainees and scholars that their decreased pro-
ductivity during the pandemicmight have a negative impact on their
long-term research and career goals and their ability to obtain
research funding. They offered a series of actions that programs,
institutions, and the NIH can take tomitigate the impact of the pan-
demic on translational trainees and scholars.
Many of the recommendations detailed in Table 1 are ones that
are valuable to implement even without the threat of another pub-
lic health emergency, highlighting that emergencies offer opportu-
nities to garner broad support to implement things that would be
beneficial under any conditions, but have faced one or more
obstacles or have not risen to a high enough priority because of
inertia. Some recommendations will require additional resources,
which are likely to be in short supply as institutions face severe
budgetary challenges, especially state medical schools that rely
on public funds. This can potentially be balanced by an appeal
for philanthropic support since the public now appreciates more
than ever the vital role that translational research plays in protect-
ing the health of the country and in developing novel diagnostic
tests and therapies. The COVID-19 pandemic has provided the
public with a thorough education in the roles of the NIH, FDA, and
CDC, with otherwise esoteric topics such as Emergency Use
Authorizations, and the statistical power of different clinical trial
Fig. 1. CTSAs and COVID-19.Major elements of the translational research enterprise
at Clinical and Translational Award (CTSA) hubs and nationally related to the COVID-19
pandemic. FDA, US Food and Drug Administration; IRB, Institutional Review Board;
N3C, National COVID Cohort Collaborative.
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Table 1. Things to do now and a Checklist for a future similar public health emergency
I. Institutional Administration
A. Create policies to align health system, hospital, university, and medical school senior administrations, along with legal departments, Institutional Review
Boards (IRBs), and technology transfer departments, to expedite decision-making related to clinical and research operations in the event of a major
sustained public health emergency.
B. Create Advisory Boards and Develop Charters and Policies
1. Clinical Research Prioritization Advisory Board. Establish criteria for prioritization of research studies, including those related to the pandemic and
those unrelated to the pandemic. For studies related to the pandemic, these may include, for example, institutional priorities; resource Intensity;
patient availability; staff capacity; minimization of duplication of studies; clinical equipoise; consent; statistical power to be informative; and adequate
funding. For studies unrelated to the pandemic, criteria may include whether it involves a life-threatening disease, whether participants already
enrolled need continuing access to otherwise unavailable drugs or other treatments, whether the studies are time-limited by virtue of a sponsor’s
requirements, and whether the studies are crucial for the career development of trainees who have time-limited appointments.
2. Biorepository Scientific Advisory Board. 1) Establish principles related to organization (centralized, federated, and/or decentralized); potential
modifications for consent (patient, legal representative if incapacitated, next of kin for autopsy); availability of translated consent documents;
potential proactive sample collection priorities even if there is no current protocol (e.g., health care workers, pediatric samples, convalescent patients);
potential specimen types and volume; processing standards; facilities; linkage to clinical data and informatics support; tracking and storage; retrieval;
and distribution. 2) Communicate with and engage all stakeholders to minimize individual investigator resistance in the future. 3) Develop a broad
consent document to encompass all potential uses of samples.
3. Biorepository Governance Advisory Board. Establish principles of operations: biosafety, including availability and access to BSL2þ and BSL3 facilities;
personnel training; regulatory and legal aspects; data sharing; sample sharing (academic investigators, government investigators, industry).
4. Institutional Safety Board. Assess on regular basis the latest information on safety risks to patients, health care workers, supporting staff, students, and
others, and develop and modify policies and procedures to maximize protections accordingly. Charge the Board with making quantitative
recommendations at timely intervals for stockpiling of personal protective equipment (PPE) and identifying restocking supply lines, including expectations
for the need for redundancy in suppliers. If institution needs to shut down, use Institutional Safety Board as core for a Reopening Committee.
5. Research Support Board. Create a Pilot Project Program and review proposals and disperse funds rapidly. Integrate efforts with Technology Transfer
Department to ensure that all intellectual property protection and licensing opportunities are maximized.
II. Individual Departments and Units
A. Communications Department
1. Develop plan for communicating with staff, faculty, students, house staff, and institutional supporters through a variety of different media, including
town hall meeting (in person or virtual), email, messaging, and social media,
2. Design websites related to clinical activities, research activities, community engagement information, and others.
3. Plan for communication with public-facing media, including radio, television, and social media about the essential role well-designed clinical studies
play in selecting the safest and most effective preventive and therapeutic interventions.
B. Community Engagement and Health Disparities Programs
1. Strengthen bidirectional partnerships with community organizations and community leaders.
2. Strengthen and support community health workers by providing resources, training, access to technology, and ability to gain access tomedical care for
patients in referral centers.
3. Develop strategy, policies, and procedures for measuring relative impact of public health emergencies in neighboring populations at high risk by virtue
of poverty, population density, racism, occupations (especially health care workers and other essential personnel), environmental air pollution, and
other relevant factors.
4. Develop language-appropriate translations of all important communications.
5. Ensure that electronic health records (EHR) include sufficiently granular race and ethnicity data to assess disproportionate impact of disease on specific
groups.
6. Develop a proactive plan with community leaders to provide a steady stream of accurate medical information and dispel misinformation in the community.
7. Develop a proactive plan with community, government, and industry partners to diminish the “digital divide” by supporting programs tomake internet
access and computers broadly available to individuals for health care information.
8. Maximize the communication value of patient portals for transmitting health information.
9. Plan with local public health agencies to bring needed services directly into the community, including diagnostic testing and long-term follow-up.
C. Development Department.
Prepare a draft of a campaign for philanthropic support of basic and clinical research for rapid implementation.
D. Human Resources Department.
1. Develop a plan to address need for increased support of essential personnel with pre-school and school-age children.
2. Develop a plan for potential redeployment of personnel and craft cross-training experiences to expedite redeployment if necessary.
3. Review policies for sick leave if need to quarantine.
4. Consider developing “Work from Anywhere” policies for rapidly hiring individuals with required skills, such as informatics.
E. Information Technology (IT) Department
1. Strengthen informatics platforms to ensure security, privacy, and technical capability to support rapid expansion of virtual operations, including tele-
medicine, institutional operations, educational activities, and both basic and clinical research, including eConsent and documentation of eConsent.
2. Develop customized dashboards for different Clinical and Translational Award (CTSA) hub leaders and institutional leaders based on data required to
manage pandemic preparedness and pandemic operations.
3. Participate in the N3C data enclave that links the EHRs on individuals diagnosed with COVID-19 frommultiple sites so that investigators can search the
records to answer key questions about the diagnosis, prognosis, and treatment of the disorder.
4. Partner with state and local public health departments, health exchanges, claims databases (CMS Medicare and Medicaid) to integrate informatics
platforms to address public health issues such as vaccination records. Assess needs for data reporting to regional and national agencies.
5. Work with clinical teams and institutional leadership to align as best as possible the information clinicians require for patient management and
research (clinical decision support with predictive tools, cohort identification, grant submissions, response to new experimental therapies) and
institutional leaders require for global planning (intensive care unit [ICU] beds, ventilators, PPE) versus the data collected by current systems. Adjust as
necessary to better align the needed and collected data.
6. Work with legal department to speed implementation of data use agreements and memoranda of understanding.
7. Review cybersecurity protections in the face of urgent requests for data sharing.
F. Legal Department
1. Prepare to expedite contracting for clinical trials with industry by exploring master agreements that can be rapidly implemented.
2. Review legal aspects related to security and HIPAA with rapid expansion of virtual operations.
G. Research Pharmacy
1. Stockpile pharmacy-specific PPE and identify potential alternative suppliers if encounter a shortage.
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2. Develop policies for emergent, expedited processes for developing drug profiles and computerized physician order entry screens for novel experimental
drugs and repurposed drugs. Ensure availability to dispense drugs 24/7/365 for studies requiring rapid drug initiation.
3. Assess current capacity for formulating novel experimental agents and assess potential value and cost of expanding capabilities.
4. Assess relationships with network pharmacists and whether to expand relationships in anticipation of future needs for drug distribution in an
emergency.
5. Develop policies for delivering experimental drugs to participants in research studies under emergency conditions, e.g., home delivery by hand or mail/
messenger or curb-side or valet pick-up from site or collaborating network pharmacy.
6. Assess most likely medications to be in short supply as a result of a major public health emergency (e.g., medications used in ICUs) and consider
stockpiling, identification of alternative suppliers, and creation of teams to modify and restrict utilization of drugs in short supply. For novel
potentially life-saving medications in short supply, develop policies with clinicians and bioethicists on criteria for fairest method to decide on
distribution (e.g., drug lottery).
7. Work with community engagement groups on combating misinformation related to evidence of drug safety and efficacy.
H. Sponsored Projects Department.
1. Develop a plan to systematically scan on a daily basis funding opportunities from government (federal, state, local), foundations, individual
philanthropy, and industry.
2. Create a communication plan to disseminate funding information.
3. Plan for expansion of a cadre of sponsored research personnel to facilitate timely grant proposal submissions.
I. Technology Transfer Department
1. Prepare to expedite Material Transfer Agreements (MTAs) for investigators at other institutions who may want access to Biorepository samples and for
institutional investigators who may want access to samples at other institutions by developing master MTAs with institutions most likely to want or
provide such samples.
2. Monitor Pilot Research Projects related to the public health emergency for potential intellectual property and licensing opportunities.
III. Human Research Protection Plan and IRB
A. Review policies and procedures, and if necessary, add sections describing actions to be taken in response to a public health emergency: a. Criteria for
differentiating Public Health Surveillance projects from Human Subjects Research; b. Temporary expansion of IRB capacity by adding personnel,
reassigning and prioritizing reviews among existing IRBs, and/or creating a new IRB to address protocols related to the emergency; c. Developing and
updating a roster of past IRB members and IRB staff who may be willing to volunteer to return to active duty to help address the need for rapid review of
protocols; d. Triage of protocols based on their need for rapid review; e. Analysis of impact of single IRB review requirements on review mechanism, with
potential to petition for exemptionwhen supported by specific circumstances; f. Potentialmodification of general principle of limiting participation to a single
experimental protocol. g. Impact of family members not being allowed to visit patients in hospital on informed consent process. h. Proactive assistance to
inexperienced investigators in developing protocols requiring IRB review. i. Importance of insuring equitable and appropriate recruitment of research
participants from groups disproportionately affected by the emergency through availability of translation of consent documents and community outreach
measures. j. Ethical considerations guiding initiation and continuation of randomized clinical trials in the face of rapidly emerging clinical information.
B. Integrate IRB efforts to speed reviewwith efforts by Clinical Research Prioritization Advisory Board and others chargedwith expediting contracting, insurance
coverage, budget negotiations, IND submissions, clinicaltrials.gov registration, obtaining and dispensing medications, and the creation of order sets in the
EHR. Monitor the contributions of all of these activities to expediting the time from protocol development to first recruited participant. Consider instituting a
Protocol Implementation Checklist to encourage an integrated approach and track relative contributions of each element to the process.
C. Review policies and procedures related to informed consent: a. Acceptable platforms for communicating with participants and legal authorized
representatives. b. Acceptable methods beyond signatures on paper informed consent forms for documenting agreement to participate in research.
c. Accommodations when infection control does not allow collection of signed paper informed consent forms. d. The relative roles of translations of
informed consent documents versus use of interpreters when there are time pressures to start studies and insure representative recruitment into studies.
e. Studies involving off-label drugs vs single patient protocols. f. Need for (re-)consenting participants as they regain capacity when the initial consent was
provided by a legally authorized representative. g. Provision of information related to consent by means other than in-person discussion between
investigator or designee and research participant, such as videos. h. Review of research participants’ experiences with the unusual consent processes
during the pandemic. i. Creation of patient and/or community advisory body to review benefits, disadvantages, and burdens of alternative consent
processes employed during the pandemic. j. Assessment of the impact of different informed consent processes on equitable and appropriate recruitment,
focusing on the potential contribution of the digital divide and cultural variations in trust in different processes.
IV. Clinical and Translational Science Award (CTSA) Hub (Institutional Translational Center or Institute)
1. Virtual operations. Assess and strengthen ability to support virtual research operations: participant recruitment, informed consent, study management,
study monitoring, physiologic measures, wearable sensors, laboratory sample collection, study visits, investigational product management, delivery of
interventions, participant remuneration, site qualification, case report forms, and site initiation. Review potential electronic platformswith IT and research
participants for HIPAA and 21 CFR Part 11 compliance, encryption, cybersecurity, privacy, and patient trust. Develop a range of options for study drug
delivery: by hand to participant’s home, curbside or valet pick-up, shipping, home-health provider for parenteral medications, and medical delivery
services. Create a Virtual Clinical Research website with resources and policies, including up to date US Food and Drug Administration (FDA) and US
Department of Health and Human Services (HHS) guidances.
2. Informed consent comprehension. Assess, and if need be, build capacity to insure the integrity of the informed consent process through methods other
than in-person meetings, e.g., videos, websites, podcasts, teleconference, telephone, multimedia, secure email, and secure text messaging. Engage
research participants in developing strategies and tools. Provide training on new methods to research community. Assess the impact of the digital divide
on the consent process. Plan for translation services to support each of the selected choices.
3. Informed consent documentation. Assess, and if need be, build capacity for capture of and documentation of consent through methods other than
signatures on paper consent forms, e.g., waiver of signature, legal digital signature, picture of signed document, FDA MyStudies application,
biological recognition, and electronic capture of oral consent. Engage research participants in developing strategies and tools. Provide training on new
methods to research community. Assess the impact of the digital divide on the documentation of consent. Plan for translation services to support each of
the selected choices.
4. Interactions with the FDA. Ensure capacity to submit documents to FDA electronically, preferably via electronic common technical document format.
Develop ongoing training program for faculty and medical staff on FDA regulatory requirements and programs, including IND/IDE and Expanded Access
programs (Emergency Use Authorization, Single Patient Protocols. Intermediate-Sized Patient Population Protocols, and Treatment Protocols). Develop
policies to respond to a public health emergency by creatingmechanisms for integrating efforts of regulatory support personnel, legal representatives, IRB
leaders, and clinicians in prioritizing studies to receive regulatory support; frequent monitoring of changing FDA requirements and programs during the
emergency; and reorganizing workflow to maximize support. Consider mechanisms to temporarily expand the number of experienced regulatory support
personnel to meet the anticipated dramatic expansion of required services.
5. Support of Rapid Publication of Results. Provide assistance to investigators in preparing reports for publication and encourage investigators to accept
invitations from journals to review manuscripts as rapidly as possible.
BSL, biosafety level; CMS, Centers for Medicare & Medicaid Services; CFR, Code of Feral Regulations; IND, Investigational New Drug; IDE, Investigational Device Exemption.
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designs, now in the news on a regular basis. It has also more indi-
rectly highlighted the crucial role of biomedical research, especially
translational research, with vaccine development center stage in a
way that has not occurred since the polio vaccine in the early 1950s
[15]. This provides opportunities to build on the public interest
with sustained public educational programs about the role and
importance of translational research more broadly. This will also
provide an opportunity to highlight the crucial role of the CTSA
program in responding to the pandemic and other important
health needs.
The CTSA program houses a Trial Innovation Network (TIN)
to coordinate multisite clinical studies. The TIN has championed a
number of innovative projects to support multiple COVID-19
studies transitioning to remote operations and the Recruitment
Innovation Center (RIC) assisted investigators in engaging diverse
communities via virtual Community Engaged Studios. The TIN
also has played a role in maximizing the amount of information
that can be extracted from studies of hydroxychloroquine and con-
valescent plasma and is playing an important role in implementing
several NIH-supported studies for COVID-19. Similarly, the CTSA
program is actively supporting the National COVID-19 Cohort
Collaborative (N3C), a major initiative to link the electronic health
records (EHRs) from patients with COVID-19 into a single search-
able data enclave to speed the identification of important diagnos-
tic, prognostic, and treatment information. The details of these
initiatives are beyond the scope of this manuscript, but they are
vital elements in a comprehensive response.
Perhaps the single greatest failing of the US response to the pan-
demic has been the fragmentation of clinical trials into mostly
institution-specific units that have not been informative because
of failure to meet the required number of participants. There have
been complex challenges in sizing and completing trials, including
tremendous variability in caseloads over short periods of time at
individual sites, so that by the time protocols became approved
the number of infections in the community dropped below the
number expected and required for timely recruitment. On the flip
side, when caseloads are exploding, and institutions require all
hands on deck, with redeployment to active patient care roles of
every person who can contribute to this mission, assigning person-
nel to support clinical trial recruitment and conduct is likely
to be viewed as a “luxury” that the institution cannot afford to
support. There is also the tension between making novel therapies
generally available through FDA Expanded Access programs based
on strong theoretical grounds, such as the use of convalescent
plasma, and wanting to conduct rigorous randomized controlled
clinical trials to unequivocally assess the value of the therapy.
These challenges are not new, being clearly delineated by Upton
Sinclair in his 1925 novel Arrowsmith, which was informed by
the 1918 influenza pandemic [16].
These challenges cry out for immediate design and implemen-
tation of nation-wide multisite trials to answer as many questions
as possible to optimize medical management as rapidly as possible.
As we are writing, NIH is undertaking such an effort in its ACTIV
[17] and CONNECTS [18] programs, with the CTSA TIN partici-
pating in the ACTIV-1 trial [19]. A full review of the effectiveness
of these programs relative to actions taken in other countries, in
particular the U.K. RECOVERY trial [20] and the ACCORD pro-
gram [21], will provide valuable data for future planning. There is a
need for national prioritization of the key scientific issues, and
mechanisms to ensure adequate enrollment into the major studies
by avoiding having multiple trials with overlapping enrolment cri-
teria at many sites, and to prevent competition between NIH trials
for sites and resources. Such an effort needs to extend beyond aca-
demic health centers to practice-based research networks if the
largest number of people are to be enrolled in the shortest period
of time and if the data are likely to be most generalizable. Now is
the time to consider putting in place all of the necessary infrastruc-
ture, including the regulatory and legal documents andmaster pro-
tocols, as well as the organizational structure, that will allow for a
true “turn-key” operation that can start enrollment within weeks of
a major new public health emergency.
As an example, the lessons learned from the convalescent
plasma therapy experience in the early phase of the COVID-19
pandemic indicate that the CTSA program as a consortium is
ideally suited to rapidly develop a convalescent plasma program
for future infectious disease challenges. By pooling resources
and knowledge, it could rapidly in parallel: 1. Develop a high-
throughput assay to measure antibody titers in convalescent
plasma that correlate with viral neutralization. 2. Create a collec-
tion of validated biobank samples that could be used to analyze the
sensitivity and specificity of the antibody assays. 3. Set up conva-
lescent donor plasma collection centers in hub blood banks,
regional blood collection facilities, and potentially in partnership
with commercial plasma collection companies to obtain convales-
cent plasma anywhere in the country where the first convalescent
patients reside, with distribution to sites around the country where
it is neededmost. Since it is crucial to obtain data from randomized
studies to assess the potential benefits and risks of convalescent
plasma, the CTSAs in collaboration with the TIN could create a
master protocol, coupled withmodel subcontracts and a regulatory
pathway, for rapid implementation in a future pandemic. Based on
the currently available data from the COVID-19 experience, such a
trial might best be limited to early institution of therapy with
plasma containing high titers of antibody in an attempt to
maximize the anticipated treatment effect. Such an effort would,
however, also require funding, a secure supply chain, and the avail-
ability of staff who are not directly engaged in providing medical
care to the patients. If such a mechanism was in place for the cur-
rent pandemic, it is possible that high-quality data would have been
available to assess the likely benefits and risks of convalescent
plasma therapy within less than 5–6 months of the rapid expansion
of the disease into the community. Thus, by combining the
national reach of the CTSA program and its remarkable depth
of full spectrum translational expertise, the consortium’s unique
synergy could be put to maximal use in improving the health of
the nation and the world.
Discussion
The COVID-19 pandemic has rapidly emerged as one of the great-
est translational research challenges in the last 100 years. It has
changed nearly everything, from our ability to conduct in-person
research visits to an unprecedented race for effective therapies and
vaccines. In those areas of the country most severely affected by the
virus, it has also required bravery, dedication, and courage on the
part of countless medical professionals and other first responders
as they put their own health at risk to save others, as well as the
bravery of the research participants themselves. Despite the terrible
toll that the pandemic has taken on both institutions and individ-
uals, we believe that CTSA hubs have shown enormous creativity
and perseverance to solve a myriad of new translational challenges,
as well as team science on a scale that we could only imagine just a
year ago. This response fits well the framework of Pandemic-
Driven Post-traumatic Growth for Organizations and Individuals
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proposed by Olson et al. [22], defined as “positive psychological
change experienced as a result of a struggle with highly challenging
life circumstances,” providing an opportunity to view the pandemic
not only as an unimaginable destructive force but also as a potential
force for improvement. Among the key elements of the framework
are, at the personal level, development of deeper relationships, open-
ness to new possibilities, greater sense of personal strength, and
greater appreciation of life. For success, it requires deliberative
reflection, leading to action characterized by awareness, transpar-
ency, motivation, creativity, and dedication to improvement.
Institutional parallels include transforming communication and del-
egation of authority and actively supporting caregivers.
Crisis management is often focused on restoring organizational
function to its pre-crisis level, but perhaps a more appropriate goal
is to achieve a higher level of function as a result of learning from the
traumatic event. Reflective assessment, identification of extraordi-
nary role models, identifying opportunities for reinvention of proc-
esses, contemplating how the experience connects the institution to
the broader community and humanity, and reappraising priorities
with regard to what is truly most important are some of the ways to
achieve the goals of post-traumatic growth. There is noway to ignore
the trauma we have all experienced individually and as members of
great institutions. We hope that this theme issue detailing the activ-
ities of the CTSA program in response to the COVID-19 pandemic
will help contribute to the goal before all of us, to make the trauma
just the first chapter in the story of post-traumatic growth that will
make all of our institutions and the CTSA program stronger, more
resilient, and more effective.
Supplementary material. To view supplementary material for this article,
please visit https://doi.org/10.1017/cts.2021.10.
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